Mr Mrs Miss Ms Dr Other

Dr
Jennifer
Carlisle

Senior Patent Attorney

Birmingham Office

Chemistry

Telephone. +44(0) 121 265 7930
Email. jcarlisle@hgf.com

Experience

Jennifer graduated in 2009 from the University of Bath with a First Class MChem honours degree in Chemistry for Drug Discovery with Industrial Training. She then completed a PhD in Organic Chemistry at the University of Bath, focusing on the asymmetric synthesis of highly substituted lactones for use in natural product synthesis. She joined HGF in May 2016.

Jennifer’s undergraduate degree provided her with a broad understanding of medicinal chemistry, including some aspects of biochemistry and pharmacology. She completed an industrial placement at AstraZeneca where she worked as a Synthetic Organic Chemist in the lead optimisation stage of drug discovery. Her PhD research involved the development of novel methodology for the asymmetric synthesis of building blocks for use in natural product synthesis. This work resulted in three publications and was presented at two international conferences.

After her PhD, Jennifer spent two years working in R&D for a specialist diabetes diagnostics company. This project focused on the design and synthesis of novel boronic acid fluorophore conjugates for use in an HbA1c assay.

Before joining HGF, Jennifer was the Industry Manager for the NIHR Diagnostic Evidence Cooperative based at Imperial College London. During this time, she was responsible for developing a portfolio of industry collaborative clinical studies for Point-of-Care in vitro diagnostic device evaluation.

Qualifications

Patent Attorney

Chartered (UK)
Europe


MCHEM

Chemistry for Drug Discovery

PHD

Organic Synthetic Chemistry

CSR

Jennifer organised a firm-wide tutorial series for trainee patent attorneys who took the UK qualifying exams in 2018 and 2019. She also regularly attends IP Inclusive events.

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details

Personal names as 'brands' in the world of fashion

Episode 1 Personal names as ‘brands’ in the world of fashion    

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.